YOU ARE HERE:
Cross-resistance
Single mutations or patterns of mutations in HIV can produce resistance to several different anti-HIV drugs. This means that once resistance to one drug has emerged, this HIV may also be resistant to drugs you haven't taken yet. This is called cross-resistance.
Cross-resistance may affect all currently available anti-HIV drugs to a greater or lesser extent. So resistance to one nucleoside analogue will affect your choice of other nucleoside analogues, resistance to a non-nucleoside analogue (NNRTI) drug will affect your choice of other NNRTIs, and resistance to a protease inhibitor will affect your choice of other protease inhibitors. Resistance to a fusion inhibitor seems likely to have implications for your chance of fusion inhibitors in the future.
New classes of anti-HIV drugs are in development, but these too may well be affected by cross-resistance